Form 4: Ligand Pharma Director Exercises, Sells Shares

Ligand Pharmaceuticals director John L. LaMattina exercised stock options and sold a total of 4,179 common shares on November 7, 2025.

Summary

• Director John L. LaMattina engaged in multiple transactions involving Ligand Pharmaceuticals Inc. common stock on November 7, 2025.
• LaMattina acquired 2,145 shares of common stock by exercising a non-qualified stock option at a price of $66.13 per share.
• Immediately following this acquisition, he disposed of 2,145 shares of common stock through a sale at $205.45 per share.
• He also acquired an additional 2,034 shares of common stock by exercising another non-qualified stock option at a price of $69.51 per share.
• Concurrently, he disposed of these 2,034 shares of common stock through a sale at $205.45 per share.
• The options exercised were previously granted and adjusted due to the OmniAb Inc. separation from the issuer.
• Following these transactions, John L. LaMattina beneficially owns 30,724 shares of Ligand Pharmaceuticals Inc. common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive for the individual director due to profitable option exercises. For the company, it's a routine insider transaction, not directly indicative of operational performance, hence a neutral impact on company sentiment. The sale of shares by a director, even if pre-planned, can sometimes be perceived as a minor negative by some investors, but the context of option exercise makes it less so.

Positives

• The director realized a significant profit by exercising options at lower prices ($66.13 and $69.51) and selling shares at a much higher price ($205.45).
• The transactions were made pursuant to a Rule 10b5-1 plan, indicating pre-planned sales and potentially reducing concerns about opportunistic insider selling.

Negatives

• The director's beneficial ownership of common stock decreased from 32,869 shares (after the first option exercise) and 32,758 shares (after the second option exercise) to a final holding of 30,724 shares, representing a net reduction in direct holdings.

Future Outlook

NA

Industry Context

This transaction is a routine insider trading disclosure for a director of a pharmaceutical company. It reflects personal financial planning and compensation realization rather than a direct statement on the company's operational performance or industry trends. The adjustment of options due to the OmniAb Inc. separation indicates a past corporate restructuring event.

Stakeholder Impact

• Shareholders: The sale of shares by a director could be interpreted in various ways, from routine compensation monetization to a signal about future prospects, though a 10b5-1 plan mitigates the latter. The net reduction in direct holdings by a director might be viewed neutrally or with slight caution.
• Employees: No direct impact on employees is indicated by this filing.

Key Dates

Recommendation

This Form 4 filing details a director's exercise of stock options and subsequent sale of shares, a common practice for executive compensation. While the director realized a significant profit, the transaction was pre-planned under a Rule 10b5-1 plan, which generally reduces the signal of opportunistic selling. The net reduction in the director's direct holdings is not substantial enough to warrant a 'sell' recommendation, nor does it provide new fundamental information to justify a 'buy'. Therefore, a 'hold' recommendation is appropriate as this filing does not alter the fundamental investment thesis for Ligand Pharmaceuticals.

Keywords

Ligand Pharmaceuticals, LGND, Insider Trading, Form 4, Stock Option Exercise, Share Sale, Director Transaction, John L. LaMattina, OmniAb Inc. separation